Executive Summary
Generated July 30, 2026
AI Labs
Isomorphic Labs
Strategic importance is our editorial rating of how central this entity is to the technology landscape we track; confidence reflects how well-sourced and current the underlying evidence is.
0
Chokepoint Score
no direct dependencies recorded in the graph
Accelerating
Activity
1 recorded change in the last 90 days
Overview
An Alphabet-spun-out AI drug discovery company built on DeepMind's AlphaFold protein-structure technology, which raised a $2.1 billion Series B round in May 2026 led by Thrive Capital with participation from Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund. Isomorphic Labs holds multi-drug R&D alliances with Eli Lilly, Novartis, and Johnson & Johnson, and is targeting its first human clinical trials by late 2026.
Strategic Connections
- Alphabet (Google): Isomorphic Labs was spun out of Alphabet, building on DeepMind's AlphaFold protein-structure prediction technology; Alphabet and its venture arm GV participated in Isomorphic's $2.1 billion Series B round in May 2026.
- Healthcare & Life Sciences: Isomorphic Labs applies AI drug design technology to accelerate pharmaceutical R&D within the healthcare and life sciences industry.
- Recursion Pharmaceuticals: Isomorphic Labs competes with Recursion Pharmaceuticals and other AI-first drug discovery companies for pharma partnerships and computational drug-design leadership.
- Xaira Therapeutics: Isomorphic Labs competes with Xaira Therapeutics and other well-funded AI drug discovery startups for pharma partnerships and top AI/computational biology talent.
- Insitro: Isomorphic Labs competes with Insitro and other machine-learning-driven drug discovery companies for pharma partnerships.
+2 more connections in the Full Analyst Report.
Strategic Risks
- No disclosed clinical-stage drug candidates yet despite a multi-billion-dollar valuation, creating validation risk ahead of first human trials
- Highly competitive AI drug discovery field with several well-funded rivals pursuing similar pharma partnership strategies
Future Outlook
- First human clinical trials targeted by late 2026 as the key proof point for the AI drug design approach
- Continued expansion of multi-target pharma alliances with Lilly, Novartis, and J&J
- Expansion hiring across London, Lausanne, and Cambridge (MA) sites to support clinical-stage transition
Sources
3 sources, 61% average source confidence — full citations in the Full Analyst Report.
Generated by InsightNodes — Technology Intelligence Platform. This report reflects sourced, evidence-backed information as of the dates cited above and is not investment advice.
Viewing the Executive Summary — switch to the Full Analyst Report.